Skip to content

Iron and Retinopathy of Prematurity (ROP)

Iron, Transferrin and Retinopathy of Prematurity (ROP): Towards New Pathophysiological Mechanisms.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05133999
Acronym
Fer-ROP
Enrollment
175
Registered
2021-11-24
Start date
2022-04-28
Completion date
2025-08-18
Last updated
2025-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinopathy of Prematurity

Keywords

retinopathy, prematurity, ROP, Iron and transferrin, Preterm infants

Brief summary

The purpose of this study is to determine whether increased transferrin saturation in plasma (that reflects iron overload and/or low transferrin) is an independent risk factor for ROP development and severity. Preterm infants born at \<31 week's post-menstrual age (PMA) or ≤1250g of birth weight will be included. Iron parameters in plasma will be measured during the first month of life. Retinopathy of prematurity (ROP) will be screened as currently recommended. The relationship between plasma iron parameters and ROP development and/or severity will be established.

Detailed description

The incidence of ROP, the main cause of vision impairment in children, is increasing parallel to the recent changes in practices targeting higher oxygen saturation in preterm babies in many countries following the publication of five trials that showed higher rates of death with lower oxygen saturations. The main risk factor for ROP development is oxygen excess. Oxygen contributes to the formation of reactive oxygen species and to lipid peroxidation which leads to vasoconstriction, vascular cytotoxicity, and arrest of vascular development causing ischemia of retinal neurons, thereby promoting the development of ROP. 90% of extremely low birth weight infants need red blood cell transfusions (RBCT) due to their immature erythropoiesis, frequent blood sampling and small circulating blood volume. RBCT are a major source of iron overload and ferritin plasma levels may remain elevated for several weeks after transfusions. It has been shown that blood transfusion is a risk factor of ROP in preterm infants. However, whether this relationship is mediated by an increased iron load remains controversial. Only two studies, conducted before the 2000s, identified plasma iron overload as a risk factor for ROP. These studies with a limited number of patients, showed contradictory results, failing to draw a conclusion. Excess iron worsens oxidative stress. Iron catalyzes the Fenton reaction which leads to the formation of reactive oxygen species. In addition a transferrin deficiency (the main iron chelator) has been suggested in premature infants. The oxidative stress observed in ROP could therefore be the consequence not only of oxygen therapy but also of iron overload. The main objective of this study is to determine whether increased transferrin saturation in plasma (that reflects iron overload and/or low transferrin) is an independent risk factor for ROP development and severity. The secondary aims/objectives are : * Determine whether low transferrin level in plasma is an independent risk factor for ROP development and severity. * Determine whether iron parameters imbalance in plasma are a risk factor for other comorbidities in Preterm infants i.e.: * 1\) sepsis * 2\) severe bronchopulmonary dysplasia * 3\) necrotizing enterocolitis (stage 2 or 3) * 4\) cystic periventricular leukomalacia * 5\) grade III or IV intraventricular haemorrhage Study duration will be 29 months, with an inclusion period of 24 months and a last visit for ROP evaluation at 45 week's post-menstrual age (PMA). A total of 175 patients should be included: 35 with ROP and 140 without ROP.

Interventions

BIOLOGICALPlasma determination of iron, transferrin and ferritin

Iron, transferrin and ferritin levels in plasma

OTHERFundus Examination by wide field digital imaging camera (PanocamTM camera)

ROP screening using wide field digital retinal imaging according to current recommendations.

Sponsors

Fondation VISIO
CollaboratorUNKNOWN
Fondation Université de Paris
CollaboratorUNKNOWN
URC-CIC Paris Descartes Necker Cochin
CollaboratorOTHER
Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
24 Weeks to 31 Weeks
Healthy volunteers
No

Inclusion criteria

* All infants born at \<31 week's post-menstrual age (PMA) or ≤1250g of birthweight * Admitted at two neonatology departments (level III) from birth * With non-opposition consent of two parents

Exclusion criteria

* Congenital malformation * Life-threatening condition (not expected to survive more than a few days) * Absence of health care protection.

Design outcomes

Primary

MeasureTime frameDescription
ROP screeningFrom 31 to 45 weeks' post menstrual age (PMA) [= (term + 4 weeks of life)].Presence of ROP development (any stage / any zone in at least one eye) during follow-up.
Levels of transferrin saturation in plasma at 1 week of lifeat 1 week of lifeBlood dosage

Secondary

MeasureTime frameDescription
Levels of ironat birth, 2, 3, and 4 weeks of lifeBlood dosage, in µmol/l
Levels of transferrinat birth, 2, 3, and 4 weeks of lifeBlood dosage, in g/l
Levels of ferritinat birth, 2, 3, and 4 weeks of lifeBlood dosage, in µg/l
ROP's highest stageduring follow-up about 5 months, up to 45 weeks' PMAaccording to International Classification of Retinopathy of Prematury (ICROP3 classification)
Need of treatment for ROPduring follow-up about 5 months, up to 45 weeks' PMALaser, anti-VEGF injections, surgery
Number of each interventionduring follow-up about 5 months, up to 45 weeks' PMANumber of each intervention if a treatment was needed
Death or presence of severe co-morbidities in preterm infantAt 36 weeks' PMAdeath or presence of monitoring : 1\) severe bronchopulmonary dysplasia or 2) necrotizing enterocolitis (stage 2 or 3), or 3) cavitary periventricular leucomalacia or 4) intraventricular haemorrhage (grade III or IV).

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026